Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8601010 | 0.90 | LMNA (0.46) | KMT2AMEN1SMN1; SMN2L3MBTL1RAB9A | |
| SCHEMBL11767308 | 0.88 | ELANE (0.52) | KMT2AMEN1SMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL19556828 | 0.86 | DHFR (0.45) | KMT2AMEN1HTTRAB9AMAOB | |
| SCHEMBL8601201 | 0.86 | LMNA (0.47) | SMN1; SMN2L3MBTL1NR4A1NR4A2NR4A3 | |
| SCHEMBL1186911 | 0.85 | MEN1 (0.52) | SRD5A2KMT2AMEN1SMN1; SMN2RAB9A | |
| SCHEMBL19504842 | 0.83 | FFAR1 (0.50) | KMT2AMEN1SMN1; SMN2RAB9AKDM4E | |
| SCHEMBL31473767 | 0.82 | CYP1A2 (0.51) | KMT2AMEN1SMN1; SMN2L3MBTL1NR4A1 | |
| SCHEMBL6202908 | 0.82 | MEN1 (0.49) | SRD5A2KMT2AMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL18354376 | 0.81 | APP (0.46) | KMT2AMEN1SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL27252707 | 0.79 | DHFR (0.54) | NR4A2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743784-B2 | TRIARYLETHANES FOR TREATING SYMPTOMS, DISEASES AND CONDITIONS IN EXTRA-REPRODUCTIVE TRACT TISSUES, SUCH AS OSTEOPENIA, THAT ARE RESPONSIVE TO TREATMENT WITH ESTROGEN | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2004-06-01 | — | — | US | disclosed |
| US-20020045664-A1 | Estrogen mimetics lacking reproductive tract effects | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC | 2002-04-18 | — | — | US | disclosed |
| US-6323190-B1 | REPRODUCTIVE TRACT TISSUES AND CARDIOVASCULAR DISORDERS | THE UNIVERISTY OF GEORGIA RESEARCH FOUNDATION, INC. | 2001-11-27 | — | — | US | disclosed |
| EP-0779808-B1 | TRIPHENYLETHYLENES FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | ORION YHTYMAE OY (FI) | 1999-08-18 | — | — | EP | disclosed |
| US-5912273-A | COMPOUNDS WITH CHLORO AND HYDROXY GROUPS FOR OSTEOPOROSIS | ORION-YHTYMA OY (FI) | 1999-06-15 | — | — | US | disclosed |
| US-5750576-A | BONE DISORDERS | ORION-YHTYMA OY (FI) | 1998-05-12 | — | — | US | disclosed |
| EP-0779808-A1 | TRIPHENYLETHYLENES FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | ORION-YHTYMÄ OY (FI) | 1997-06-25 | — | — | EP | disclosed |
| WO-1996007402-A1 | TRIPHENYLETHYLENES FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | Orion-Yhtymä Oy (FI) | 1996-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045664-A1 | Estrogen mimetics lacking reproductive tract effects | ESR2, ESRRA, GPER1 | SRD5A2 38/4885KMT2A 1621/4885MEN1 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.